Literature DB >> 6094796

Pharmacological evidence for a distinct leukotriene C4 receptor in guinea-pig trachea.

D W Snyder, R D Krell.   

Abstract

The effect of the leukotriene (LT) antagonist, FPL55712, on the contractile activity of peptide leukotrienes was evaluated in the presence and absence of enzyme inhibitors of leukotriene metabolism. L-Cysteine, an inhibitor of aminopeptidase, prevents the formation of LTE4 from LTD4 and LTC4. L-Serine borate, an inhibitor of gamma-glutamyl transpeptidase prevents the conversion of LTC4 to LTD4. L-Cysteine (3mM) enhanced the contractile activity of LTC4 and LTD4. L-Serine borate (45 mM) increased selectively the contractile activity of LTC4. FPL55712 (10 microM) antagonized the contractile activity of LTC4, LTD4 and LTE4 in the absence of enzyme inhibitors. In the presence of L-serine borate, FPL55712 (10-30 microM) failed to antagonize the contractile activity of LTC4 but did antagonize LTD4 and LTE4. However, the dissociation constant (KB) for FPL55712 against LTD4 was increased by L-serine borate whereas the KB against LTE4 was not altered. In the presence of L-cysteine, FPL55712 antagonized the contractile activity of the peptide LTs. However, FPL55712 was more effective (P less than .05) in antagonizing LTD4 and LTE4 than LTC4 in the presence of L-cysteine. The data suggest that when the conversion of LTC4 to LTD4 and subsequently to LTE4 is blocked by L-serine borate FPL55712 is ineffective in antagonizing the actions of LTC4. This would indicate that LTC4 occupies a distinct LT receptor in guinea-pig trachea which is insensitive to the actions of FPL55712.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6094796

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

Review 1.  Leukotriene receptors.

Authors:  S E Dahlén
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Airway receptors.

Authors:  P J Barnes
Journal:  Postgrad Med J       Date:  1989-08       Impact factor: 2.401

3.  Antigen-induced contraction of guinea-pig isolated trachea: studies with novel inhibitors and antagonists of arachidonic acid metabolites.

Authors:  T R Jones; L Charette; D Denis
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

4.  Stimulation by leukotriene D4 of increases in the cytosolic concentration of calcium in dimethylsulfoxide-differentiated HL-60 cells.

Authors:  L Baud; E J Goetzl; C H Koo
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

Review 5.  New developments concerning leukotriene antagonists: a review.

Authors:  J H Musser; A F Kreft; A J Lewis
Journal:  Agents Actions       Date:  1986-06

6.  An alternative pathway for metabolism of leukotriene D(4): effects on contractions to cysteinyl-leukotrienes in the guinea-pig trachea.

Authors:  M Bäck; M Kumlin; I A Cotgreave; S E Dahlén
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

7.  Evaluation of LY163443, 1-[2-hydroxy-3-propyl-4-([4- (1H-tetrazol-5-ylmethyl)phenoxy]methyl) phenyl]ethanone, as a pharmacologic antagonist of leukotrienes D4 and E4.

Authors:  J H Fleisch; L E Rinkema; K D Haisch; D McCullough; F P Carr; R D Dillard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-05       Impact factor: 3.000

Review 8.  Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7.

Authors:  Magnus Bäck; William S Powell; Sven-Erik Dahlén; Jeffrey M Drazen; Jilly F Evans; Charles N Serhan; Takao Shimizu; Takehiko Yokomizo; G Enrico Rovati
Journal:  Br J Pharmacol       Date:  2014-07-12       Impact factor: 8.739

9.  L-648,051, a novel cysteinyl-leukotriene antagonist is active by the inhaled route in man.

Authors:  J M Evans; N C Barnes; J T Zakrzewski; D G Sciberras; E G Stahl; P J Piper; J F Costello
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

Review 10.  Using guinea pigs in studies relevant to asthma and COPD.

Authors:  Brendan J Canning; Yangling Chou
Journal:  Pulm Pharmacol Ther       Date:  2008-02-02       Impact factor: 3.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.